Phathom Pharmaceuticals, Inc. already launched the heartburn reliever Voquezna (vonoprazan) in November 2023, but US Food and Drug Administration approval in an expanded indication will make the treatment available to a substantially larger set of patients. The FDA approved Voquezna on 17 July for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults, a condition that affects millions of individuals.
Key Takeaways
- CEO Terrie Curran talked to Scrip in an interview about the launch of Voquezna, the first new mechanism of action for GERD in decades.
The approval marks the third indication for Voquezna, a first-in-class potassium-competitive acid blocker (PCAB) that FDA originally approved in 2022...